130 related articles for article (PubMed ID: 20120409)
21. Fabry disease: a study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations.
Larralde M; Boggio P; Amartino H; Chamoles N
Arch Dermatol; 2004 Dec; 140(12):1440-6. PubMed ID: 15611419
[TBL] [Abstract][Full Text] [Related]
22. [Stroke in Fabry disease. More than a simple stenosis].
Politei JM
Medicina (B Aires); 2006; 66(5):467-71. PubMed ID: 17137181
[TBL] [Abstract][Full Text] [Related]
23. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
24. Renal involvement in Anderson-Fabry disease.
Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
[TBL] [Abstract][Full Text] [Related]
25. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.
Torvin Møller A; Winther Bach F; Feldt-Rasmussen U; Rasmussen A; Hasholt L; Lan H; Sommer C; Kølvraa S; Ballegaard M; Staehelin Jensen T
Pain; 2009 Sep; 145(1-2):237-45. PubMed ID: 19665302
[TBL] [Abstract][Full Text] [Related]
26. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
[TBL] [Abstract][Full Text] [Related]
27. Fabry disease: case report with emphasis on enzyme replacement therapy and possible future therapeutic options.
Möhrenschlager M; Pontz BF; Lanzl I; Podskarbi T; Henkel V; Ring J
J Dtsch Dermatol Ges; 2007 Jul; 5(7):594-7. PubMed ID: 17610610
[TBL] [Abstract][Full Text] [Related]
28. [Classical type of Fabry disease without angiokeratomas--a case report].
Kudumija B; Mrsić M; Dits S; Matijević V; Thune S; Bozina K
Lijec Vjesn; 2007 Dec; 129(12):396-400. PubMed ID: 18383742
[TBL] [Abstract][Full Text] [Related]
29. Fabry disease: an atypical presentation.
Choudhury S; Meehan S; Shin HT
Pediatr Dermatol; 2005; 22(4):334-7. PubMed ID: 16060871
[TBL] [Abstract][Full Text] [Related]
30. Angiokeratoma corporis diffusum (Fabry disease).
Karen JK; Hale EK; Ma L
Dermatol Online J; 2005 Dec; 11(4):8. PubMed ID: 16403380
[TBL] [Abstract][Full Text] [Related]
31. Ocular manifestations of Fabry disease within in a single kindred.
Morier AM; Minteer J; Tyszko R; McCann R; Clarke MV; Browning MF
Optometry; 2010 Sep; 81(9):437-49. PubMed ID: 20615758
[TBL] [Abstract][Full Text] [Related]
32. [Fabry disease--a provocation for pediatrics].
Hoffmann B; Mayatepek E
Klin Padiatr; 2006; 218(1):38-40. PubMed ID: 16432775
[TBL] [Abstract][Full Text] [Related]
33. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report.
Porsch DB; Nunes AC; Milani V; Rossato LB; Mattos CB; Tsao M; Netto C; Burin M; Pereira F; Matte U; Giugliani R; Barros EJ
Ren Fail; 2008; 30(9):825-30. PubMed ID: 18925518
[TBL] [Abstract][Full Text] [Related]
34. [White matter lesions, young age, female--differential diagnosis of multiple sclerosis and juvenile stroke].
Flossdorf P; Kurschat C; Fink GR; Sparing R
Fortschr Neurol Psychiatr; 2013 Mar; 81(3):138-44. PubMed ID: 23516103
[TBL] [Abstract][Full Text] [Related]
35. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
36. [Diagnostic problems in a 17-year-old patient with gastrointestinal manifestations of Fabry disease].
Buda P; Wieteska-Klimczak A; Ksiazyk J; Smorczewska-Kiljan A; Gietka P; Czartoryska B; Tylki-Szymańska A
Med Wieku Rozwoj; 2011; 15(1):69-72. PubMed ID: 21786514
[TBL] [Abstract][Full Text] [Related]
37. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
38. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
39. Neurological manifestations in Fabry's disease.
Møller AT; Jensen TS
Nat Clin Pract Neurol; 2007 Feb; 3(2):95-106. PubMed ID: 17279083
[TBL] [Abstract][Full Text] [Related]
40. Neurological manifestations of Fabry disease in female carriers.
Bird TD; Lagunoff D
Ann Neurol; 1978 Dec; 4(6):537-40. PubMed ID: 217299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
